Open, Randomized Phase II Trial to Investigate the Efficacy and Safety of the PLK-1 Inhibitor BI 2536 in Patients With Advanced, Unresectable Pancreatic Cancer
Clinical trial NCT00710710 · COMPLETED
Trial details
- NCT number
- NCT00710710
- Sponsor
- Boehringer Ingelheim
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2006-08-01
- Primary completion
- 2008-10-14
- Enrollment
- 89
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.